Analysis reveals a multi-modality fused model improves prediction of biochemical recurrence in prostate cancer, indicating enhanced treatment planning.
Motivation: There are currently a few studies that utilize artificial intelligence technology to analyze both for precise prediction of prostate cancer prognosis. Goal(s): To explore the value of a multi-modality fused model integrating clinical feature, radiomics model, MRI DL model and pathomics model in enhancing predictive efficacy of post-RP BCR. Approach: The CRDH fused model was established by combining clinical model, radiomics model, MRI DL model and pathomics model with COX regression. Results: In the testing set, the CRDH model achieved a C-index of 0.87, significantly higher than pathological T stage, radiomics model, MRI DL model, pathomics model and clinical score (P<0.05). Impact: The multi-modality fused model incorporating clinical variable, radiomics model, MRI DL model, pathomics model was better than all single-modality models. Our model could assess the prognosis of patients with PCa after surgery, providing strong support for formulating subsequent treatment plans.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: